TCGA-95-8039-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.540
- INTERFERON_GAMMA_RESPONSE+0.450
- IL6_JAK_STAT3_SIGNALING+0.380
- COAGULATION+0.340
- ALLOGRAFT_REJECTION+0.320
- IL2_STAT5_SIGNALING+0.240
- COMPLEMENT+0.230
- INFLAMMATORY_RESPONSE+0.230
- MYOGENESIS+0.190
- KRAS_SIGNALING_UP+0.180
Top 10 suppressed
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.550
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.480
- MTORC1_SIGNALING-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- WNT_BETA_CATENIN_SIGNALING-0.360
- APICAL_SURFACE-0.250
- PI3K_AKT_MTOR_SIGNALING-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-A4M6-01A-11R-A24X-07 | — | cohortA1 | 0.929 |
| 2 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.889 |
| 3 | TCGA-86-8280-01A-11R-2287-07 | — | cohortA1 | 0.886 |
| 4 | SRR8518288 | — | A | 0.873 |
| 5 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.868 |
| 6 | TCGA-67-6216-01A-11R-1755-07 | — | cohortA1 | 0.864 |
| 7 | TCGA-44-3919-01A-02R-1107-07 | — | cohortA1 | 0.854 |
| 8 | TCGA-86-8671-01A-11R-2403-07 | — | cohortMD2 | 0.851 |
| 9 | TCGA-78-8655-01A-11R-2403-07 | — | cohortA1 | 0.846 |
| 10 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.040 | Inavolisib | — uncovered |
| APOPTOSIS | 0.030 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |